<DOC>
	<DOCNO>NCT02900118</DOCNO>
	<brief_summary>Breast cancer among cancer metastasize skeleton . The appearance bone metastasis , whether initial relapse , turn point disease , due additional morbidity imply ( pain , pathologic fracture , hypercalcaemia , neurological compression , etc. ) . A specific treatment metastasis often undertaken , usually chemotherapy hormone therapy . It important evaluate efficacy treatment order know whether continue change depend response observe . But consensus time paraclinical examination enable monitoring . Also , criterion assess bone metastasis image nuclear medicine ( MDA , PERCIST , EORTC ) publish literature , none formally validate evaluation routine practice remain subjective . The main objective study determine PET-CT whole-body MRI agreement status bone metastasis ( stability , progression , partial response , complete response ) .</brief_summary>
	<brief_title>Imaging Evaluation Therapeutic Response Breast Cancer Bone Metastasis ( EMOS )</brief_title>
	<detailed_description>The oncologist include patient respond criterion oppose collection data . He submit request whole-body MRI PET-CT Medical Imaging Nuclear Medicine department Oscar Lambret Centre . If patient benefit within previous 15 day examination , perform : serve initial examination . Following examination , oncologist completes read grid . A clinical examination question main stage disease perform data report dedicated sheet . A prescription tumor marker bone remodel perform ( absence recent result ) , result report sheet . After 3 cycle ( intravenous chemotherapy ) 3 month hormone therapy , oncologist submit new request whole-body MRI PET-CT . The MRI PET-CT conclude status : progression , stability , partial response , complete response . The reading grid complete . MDA criterion ( MRI PET-CT ) , PERCIST EORTC ( PET-CT ) determine . Target lesion ( 1 3 ) define examination measure ADC SUV perform lesion initial follow-up examination . After examination , patient review oncologist new clinical examination , announcement status bone metastasis possible adaptation treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Patient breast cancer bone metastasis : initial diagnosis ( group 1 ) . metastatic bone relapse ( group 2 ) . progression bone metastasis ( group 3 ) . 2 . Treatment ( hormone therapy , chemotherapy ) undertaken ( group 1 ) prior therapeutic change ( group 2 3 ) . 3 . Patient oppose use data . 1 . Claustrophobic patient 2 . Patient uncontrolled diabetes ( fast glucose &lt; 1.6 g / l ) 3 . Patient pacemaker another material incompatible MRI 3 Tesla 4 . Very algetic patient ( Visual Analog Scale ( VAS ) &gt; 7 ) 5 . Pregnant breastfeed woman 6 . Patient 18 guardianship 7 . Movement disorder ( Parkinson disease , etc . ) dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bone metastasis</keyword>
	<keyword>PET-CT</keyword>
	<keyword>whole-body MRI</keyword>
</DOC>